Asset Details
Do you wish to reserve the book?
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Do you wish to request the book?
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2023
Overview
In two phase 3 trials, mirikizumab, a p19-directed anti–interleukin-23 antibody, was superior to placebo with regard to clinical remission of ulcerative colitis at 12 weeks (induction) and 40 weeks (maintenance).
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
/ Anti-Inflammatory Agents, Non-Steroidal - adverse effects
/ Anti-Inflammatory Agents, Non-Steroidal - immunology
/ Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
/ Cancer
/ Colitis, Ulcerative - drug therapy
/ Herpes Zoster - chemically induced
/ Humans
/ Induction Chemotherapy - adverse effects
/ Induction Chemotherapy - methods
/ Maintenance Chemotherapy - adverse effects
/ Maintenance Chemotherapy - methods
/ Opportunistic Infections - chemically induced
/ Opportunistic Infections - etiology
/ Patients
/ Placebos
